Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Long-Term Effects of Bariatric Surgery on Meal Disposal and  -Cell Function in Diabetic and Nondiabetic Patients

(2013) S. Camastra et al.   DIABETES

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

(2013) D. Polidori et al.   DIABETES CARE

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells

(2013) A. M. Habib et al.   DIABETOLOGIA

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

(2013) Damayanthi Devineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

(2012) Takumi Nagata et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?

(2012) J. Liu et al.   DIABETES

Dapagliflozin

(2012) Greg L. Plosker   DRUGS

Overlap of Endocrine Hormone Expression in the Mouse Intestine Revealed by Transcriptional Profiling and Flow Cytometry

(2012) Abdella M. Habib et al.   ENDOCRINOLOGY

Dapagliflozin: a review on efficacy, clinical effectiveness and safety

(2012) Angela J Paisley et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes

(2012) Elza Muscelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice

(2012) Atsuo Tahara et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

Familial renal glucosuria: a clinicogenetic study of 23 additional cases

(2012) HyunKyung Lee et al.   PEDIATRIC NEPHROLOGY

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study

(2011) E. Ferrannini et al.   DIABETOLOGIA

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2

(2010) Charles S. Hummel et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

(2010) Mathias Nicolaus et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms

(2009) Sandra Bonuccelli et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM